Chemoprotection of normal tissues by transfer of drug resistance genes.
AuthorsRafferty, Joseph A
Lashford, Linda S
Margison, Geoffrey P
Dexter, T Michael
Fairbairn, Leslie J
AffiliationCRC Department of Carcinogenesis, Paterson Institute for Cancer Research, Christie Hospital (NHS)-Trust, Manchester, UK.
MetadataShow full item record
AbstractThe effectiveness of many types of antitumour agent is limited by (i) acute dose limiting cytotoxicity, principally myelosuppression but also lung, liver and gastrointestinal tract toxicity, (ii) the risk of therapy related secondary malignancy and (iii) the inherent or acquired drug-resistance of tumour cells. As the management of the acute toxic effects improve, the more insidious effects, and particularly haematological malignancies, are anticipated to increase. Furthermore, attempts to overcome tumour cell resistance to treatment can lead to increased collateral damage in normal tissues. One approach to circumventing both the acute toxic and chronic carcinogenic effects of chemotherapy would be to use gene therapy to achieve high levels of expression of drug resistance proteins in otherwise drug-sensitive tissues. To date the products of the multi-drug resistance (MDR-1) and the human O6-alkylguanine-DNA-alkyltransferase (ATase) gene have been used in preclinical experiments to demonstrate proof of principle, and the former of these is now being tested in a clinical situation. Here we discuss the potential of drug-resistance gene therapy to provide chemoprotection to normal tissues and examine the prospects for a dual approach which combines this with pharmacological sensitisation of tumours to chemotherapeutic agents.
CitationChemoprotection of normal tissues by transfer of drug resistance genes. 1996, 15 (3):365-83 Cancer Metastasis Rev.
JournalCancer Metastasis Reviews
- Dual agent chemoprotection by retroviral co-expression of either MDR1 or MRP1 with the P140K mutant of O6-methylguanine-DNA-methyl transferase.
- Authors: Southgate TD, Garside E, Margison GP, Fairbairn LJ
- Issue date: 2006 Aug
- Transfer of drug resistance genes into hematopoietic progenitors to improve chemotherapy tolerance.
- Authors: Koç ON, Allay JA, Lee K, Davis BM, Reese JS, Gerson SL
- Issue date: 1996 Feb
- A novel dual function retrovirus expressing multidrug resistance 1 and O6-alkylguanine-DNA-alkyltransferase for engineering resistance of haemopoietic progenitor cells to multiple chemotherapeutic agents.
- Authors: Jelinek J, Rafferty JA, Cmejla R, Hildinger M, Chinnasamy D, Lashford LS, Ostertag W, Margison GP, Dexter TM, Fairbairn LJ, Baum C
- Issue date: 1999 Aug
- Genetic chemoprotection with mutant O6-alkylguanine-DNA-alkyltransferases.
- Authors: Hobin DA, Fairbairn LJ
- Issue date: 2002 Feb
- Engineering drug resistance in human cells.
- Authors: Fairbairn LJ, Rafferty JA, Lashford LS
- Issue date: 2000 May